Log In
Print this Print this

Mucogard, MuGard

  Manage Alerts
Collapse Summary General Information
Company Abeona Therapeutics Inc.
DescriptionMucoadhesive oral rinse
Molecular Target Undisclosed
Mechanism of ActionUndisclosed
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationMucositis
Indication DetailsTreat and prevent stomatitis in breast cancer patients receiving everolimus; Treat oral mucositis (OM) in cancer patients
Regulatory Designation
Partner AMAG Pharmaceuticals Inc.; Dong-A Pharmaceutical Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Norgine B.V.; RHEI Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today